Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome

Addiction

Volumn 105, Issue 12, 2010, Pages 2151-2159

  Gray, Teresa R ^a   Choo, Robin E ^b   Concheiro, Marta ^a   Williams, Erica ^c   Elko, Andrea ^c   Jansson, Lauren M ^c   Jones, Hendreé E ^c   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cocaine; Meconium; Methadone; Neonatal abstinence syndrome; Opioid; Pregnancy

Indexed keywords

COCAINE; METHADONE; NARCOTIC AGENT; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CHEMISTRY; COCAINE DEPENDENCE; FEMALE; GESTATIONAL AGE; HUMAN; LENGTH OF STAY; MECONIUM; METHODOLOGY; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREDICTIVE VALUE; PREGNANCY; PREGNANCY COMPLICATION; PREMATURITY; PRENATAL EXPOSURE; PROSPECTIVE STUDY; SUBSTANCE ABUSE; URINE; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; COCAINE; COCAINE-RELATED DISORDERS; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; LENGTH OF STAY; MECONIUM; METHADONE; NARCOTICS; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; SUBSTANCE ABUSE DETECTION; YOUNG ADULT;

EID: 78249266928     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03097.x     Document Type: Article

References (50)

1. Hulse G. K., Milne E., English D. R., Holman C. D. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction 1998; 93: 1033-42.
2. Connaughton J. F., Jr, Finnegan L. P., Schut J., Emich J. P. Current concepts in the management of the pregnant opiate addict. Addict Dis 1975; 2: 21-35.
3. Strauss M. E., Andresko M., Stryker J. C., Wardell J. N., Dunkel L. D. Methadone maintenance during pregnancy: pregnancy, birth, and neonate characteristics. Am J Obstet Gynecol 1974; 120: 895-900.
4. Kaltenbach K., Finnegan L. P. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol 1986; 8: 353-5.
5. Kaltenbach K. A., Finnegan L. P. Prenatal narcotic exposure: perinatal and developmental effects. Neurotoxicology 1989; 10: 597-604.
6. Finnegan L. P., Hagan T., Kaltenbach K. A. Scientific foundation of clinical practice: opiate use in pregnant women. Bull NY Acad Med 1991; 67: 223-39.
7. Jansson L. M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5: 47-55.
8. Dashe J. S., Sheffield J. S., Olscher D. A., Todd S. J., Jackson G. L., Wendel G. D. Jr. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 2002; 100: 1244-9.
9. Lim S., Prasad M. R., Samuels P., Gardner D. K., Cordero L. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009; 200: 70 e1-5.
10. Dryden C., Young D., Hepburn M., Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. Br J Obstet Gynaecol 2009; 116: 665-71.
11. Berghella V., Lim P. J., Hill M. K., Cherpes J., Chennat J., Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 2003; 189: 312-7.
12. Lejeune C., Simmat-Durand L., Gourarier L., Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82: 250-7.
13. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-81.
14. Kuschel C. A., Austerberry L., Cornwell M., Couch R., Rowley R. S. Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome? Arch Dis Child Fetal Neonatal Ed 2004; 89: F390-3.
15. McCarthy J. J., Leamon M. H., Parr M. S., Anania B. High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes. Am J Obstet Gynecol 2005; 193: 606-10.
16. Bakstad B., Sarfi M., Welle-Strand G. K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res 2009; 15: 128-34.
17. Seligman N. S., Salva N., Hayes E. J., Dysart K. C., Pequignot E. C., Baxter J. K. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008; 199.
18. Kreek M. J., Schecter A., Gutjahr C. L., Bowen D., Field F., Queenan J. et al. Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptons in a neonate of mother maintained on methadone. Am J Drug Alcohol Abuse 1974; 1: 409-19.
19. Rosen T. S., Pippenger C. E. Pharmacologic observations on the neonatal withdrawal syndrome. Pediatrics 1976; 88: 1044-8.
20. Harper R. G., Solish G., Feingold E., Gersten-Woolf N. B., Sokal M. M. Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome. Am J Obstet Gynecol 1977; 129: 417-24.
21. Offidani C., Chiarotti M., De Giovanni N., Falasconi A. M. Methadone in pregnancy: clinical-toxicological aspects. J Toxicol Clin Toxicol 1986; 24: 295-303.
22. Mack G., Thomas D., Giles W., Buchanan N. Methadone levels and neonatal withdrawal. J Paediatr Child Health 1991; 27: 96-100.
23. Doberczak T. M., Kandall S. R., Friedmann P. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993; 81: 936-40.
24. Malpas T. J., Darlow B. A., Lennox R., Horwood L. J. Maternal methadone dosage and neonatal withdrawal. Aust NZ J Obstet Gynaecol 1995; 175-7.
25. Blinick G., Inturrisi C. E., Jerez E., Wallach R. C. Methadone assays in pregnant women and progeny. Am J Obstet Gynecol 1975; 121: 617-21.
26. Gray T., Huestis M. Bioanalytical procedures for monitoring in utero drug exposure. Anal Bioanal Chem 2007; 388: 1455-65.
27. Lozano J., Garcia-Algar O., Vall O., De La Torre R., Scaravelli G., Pichini S. Biological matrices for the evaluation of in utero exposure to drugs of abuse. Ther Drug Monit 2007; 29: 711-34.
28. Kacinko S. L., Jones H. E., Johnson R. E., Choo R. E., Huestis M. A. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008; 84: 604-12.
29. Casanova O. Q., Lombardero N., Behnke M., Eyler F. D., Conlon M., Bertholf R. L. Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med 1994; 118: 988-93.
30. Jansson L. M., Svikis D., Lee J., Paluzzi P., Rutigliano P., Hackerman F. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat 1996; 13: 321-9.
31. Jansson L., Svikis D., Velez M., Fitzgerald E., Jones H. The impact of managed care on drug-dependent pregnant and postpartum women and their children. Subst Use Misuse 2007; 42: 961-74.
32. Fitzsimons H., Tuten M., Vaidya V., Jones H. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat 2007; 32: 19-25.
33. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
34. Jansson L. M., Choo R. E., Harrow C., Velez M., Schroeder J. R., Lowe R. et al. Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact 2007; 23: 184-90.
35. Choo R. E., Murphy C. M., Jones H. E., Huestis M. Determination of methadone, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine, 2-ethyl-5-methyl-3, 3-diphenylpyraline and methadol in meconium by liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 814: 369-73.
36. Gray T. R., Shakleya D. M., Huestis M. A. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem 2009; 393: 1977-90.
37. Stolk L. M., Coenradie S. M., Smit B. J., Van As H. L. Analysis of methadone and its primary metabolite in meconium. J Anal Toxicol 1997; 21: 154-9.
38. Kreek M. J. Methadone disposition during the perinatal period in humans. Pharmacol Biochem Behav 1979; 11 (Suppl): 7-13.
39. Swift R. M., Dudley M., DePetrillo P., Camara P., Griffiths W. Altered methadone pharmacokinetics in pregnancy: implications for dosing. J Subst Abuse 1989; 1: 453-60.
40. Jarvis M. A. E., Wu-Pong S., Kniseley J. S., Schnoll S. H. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999; 18: 51-61.
41. Wolff K., Boys A., Rostami-Hodjegan A., Hay A., Raistrick D. Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol 2005; 61: 763-8.
42. Anderson G. D. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Exp Opin Drug Metab Toxicol 2006; 2: 947-60.
43. Nekhayeva I., Nanovskaya T., Deshmukh S., Zharikova O., Hankins G. D. V., Ahmed M. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005; 69: 187-97.
44. Nanovskaya T. N., Nekhayeva I. A., Hankins G. D. V., Ahmed M. S. Transfer of methadone across the dually perfused preterm human placental lobule. Am J Obstet Gynecol 2008; 198: 126.e1-e4.
45. Kohler E., Avenarius S., Rabsilber A., Gerloff C., Jorch G. Assessment of prenatal tobacco smoke exposure by determining nicotine and its metabolites in meconium. Hum Exp Toxicol 2007; 26: 535-44.
46. Ostrea E. M., Brady M. J., Parks P. M., Asensio D. C., Naluz A. Drug screening of meconium in infants of drug-dependent mothers: an alternative to urine testing. J Pediatr 1989; 115: 474-7.
47. Russell R., Green N., Steiner C., Meikle S., Howse J., Poschman K. et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 2007; 120: e1-e9.
48. Dysart K., Hsieh H. C., Kaltenbach K., Greenspan J. S. Sequela of preterm versus term infants born to mothers on a methadone maintenance program: differential course of neonatal abstinence syndrome. J Perinat Med 2007; 35: 344-6.
49. Choo R. E., Huestis M. A., Schroeder J. R., Shin A. S., Jones H. E. Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend 2004; 75: 253-60.
50. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005.